Immuneering Corp cash flow statement

In fiscal 2023, Immuneering Corp's operations generated −$49.0m of cash; it spent $342,746 on capital projects, leaving free cash flow of −$49.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Immuneering Corp: cash flow statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023
Cash from operations	−15	−31	−44	−49
Depreciation and amortisation	0	0	0	0
Stock-based pay	1	2	4	6
Capital spending	0	0	1	0
Free cash flow	−15	−31	−45	−49
Free cash flow after stock pay	−16	−33	−49	−55
Shares issued	—	120	0	28

US$ millions unless shown otherwise. Fiscal quarters.

Immuneering Corp: cash flow statement, quarterly
Quarter	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022	2023 Q1Mar 2023	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023
Cash from operations	−12	−9	−11	−12	−14	−11	−12	−12
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	1	1	1	1	1	1	1	2
Capital spending	0	0	0	0	0	0	0	0
Free cash flow	−12	−10	−11	−12	−14	−11	−12	−12
Free cash flow after stock pay	−13	−11	−12	−13	−16	−12	−14	−14
Shares issued	—	—	0	0	—	—	0	0

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immuneering Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immuneering Corp.